Acrivastine

{{drugbox | | IUPAC_name = (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | image = | CAS_number = 87848-99-5 | ATC_prefix = R06 | ATC_suffix = AX18 | PubChem = 5284514 | DrugBank = | C = 22 | H = 24 | N = 2 | O = 2 | molecular_weight = 348.438 g/mol | smiles = CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 1.5 hours | excretion = Renal | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}

WikiDoc Resources for Acrivastine
Articles
Most recent articles on Acrivastine Most cited articles on Acrivastine Review articles on Acrivastine Articles on Acrivastine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Acrivastine Images of Acrivastine Photos of Acrivastine Podcasts & MP3s on Acrivastine Videos on Acrivastine
Evidence Based Medicine
Cochrane Collaboration on Acrivastine Bandolier on Acrivastine TRIP on Acrivastine
Clinical Trials
Ongoing Trials on Acrivastine at Clinical Trials.gov Trial results on Acrivastine Clinical Trials on Acrivastine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Acrivastine NICE Guidance on Acrivastine NHS PRODIGY Guidance FDA on Acrivastine CDC on Acrivastine
Books
Books on Acrivastine
News
Acrivastine in the news Be alerted to news on Acrivastine News trends on Acrivastine
Commentary
Blogs on Acrivastine
Definitions
Definitions of Acrivastine
Patient Resources / Community
Patient resources on Acrivastine Discussion groups on Acrivastine Patient Handouts on Acrivastine Directions to Hospitals Treating Acrivastine Risk calculators and risk factors for Acrivastine
Healthcare Provider Resources
Symptoms of Acrivastine Causes & Risk Factors for Acrivastine Diagnostic studies for Acrivastine Treatment of Acrivastine
Continuing Medical Education (CME)
CME Programs on Acrivastine
International
Acrivastine en Espanol Acrivastine en Francais
Business
Acrivastine in the Marketplace Patents on Acrivastine
Experimental / Informatics
List of terms related to Acrivastine

Overview

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine and works by blocking H1 histamine receptors.

It is sold under the brand name Benadryl Allergy Relief in the U.K. by Pfizer, not to be confused with Benadryl Once a Day, which is cetirizine and is also sold by Pfizer in the U.K. This drug is currently not available as a generic in the U.K.

In the U.S., acrivastine is the active ingrediant in the Semprex brand. Semprex-D is also acrivastine based, but also contains a decongestant.

Pill Images

{{#ask: Page Name::Acrivastine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject:

 |Page Name=Acrivastine
 |Pill Name=SEMPREX_NDC_522440404.jpg
 |Drug Name=SEMPREX
 |Pill Ingred=ACRIVASTINE[ACRIVASTINE];PSEUDOEPHEDRINE HYDROCHLORIDE[PSEUDOEPHEDRINE]|+sep=;
 |Pill Imprint=404;SEMPREX;D
 |Pill Dosage=8 mg
 |Pill Color=Green|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Actient Pharmaceuticals, LLC
 |NDC=522440404

}}

{{#subobject:

 |Page Name=Acrivastine
 |Pill Name=Semprex-D_NDC_530140404.jpg
 |Drug Name=Semprex-D
 |Pill Ingred=acrivastine[acrivastine];pseudoephedrine hydrochloride[pseudoephedrine]|+sep=;
 |Pill Imprint=404;SEMPREX-D
 |Pill Dosage=8 mg
 |Pill Color=Green;White|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=UCB, Inc.
 |NDC=530140404

}}